Dr. Reddy’s Laboratories (RDY) is trading higher today, outperforming on renewed focus around semaglutide-related optionality and a defensive rotation into pharma. Investor attention has centered on the post-patent landscape in India after semaglutide’s patent expiry on March 20, 2026 and on the Delhi High Court’s decision backing Dr. Reddy’s ability to manufacture semaglutide for export to jurisdictions where patent protection does not apply, developments that have supported expectations for incremental volume and partnerships. In parallel, pharma stocks have been catching a bid as a defensive pocket of the market, and positioning dynamics such as short covering can magnify an up-move once momentum turns.

Semaglutide is one of the most commercially important molecules in global diabetes and weight-management, and the opening created by patent expiries and court clarity can reshape near-term growth narratives for large generic manufacturers. For Dr. Reddy’s, investors are weighing (a) the pace of launches in markets as patents fall on different timelines, (b) the economics of API/formulation supply and potential export channels, and (c) whether the company can translate manufacturing readiness into sustained margins amid an increasingly crowded generic field.

Key near-term swing factors include any concrete launch updates (product timing, pricing, distribution partnerships) and further legal milestones that could affect export scope or constraints. Investors will also monitor upcoming earnings timing and guidance commentary for any explicit quantification of GLP-1/semaglutide contribution, as well as whether today’s move holds on volume—signaling more than a one-day positioning squeeze.